Adults 18 to 65, any sex, with Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Overall Response Score (ORS)Primary· Week 52
The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).
Clinically significant worsening = -1, no change = 0, clinically significant improvement = +1.
The ORS is the sum of these scores for the EDSS: Timed 25-Foot Walk, 9-Hole Peg Test-dominant, and 9-Hole Peg Test-nondominant and ranges from -4 to + 4.
Disability improvement response rate is assessed based on the Expanded Disability Status Scale Plus (EDSS+). EDSS+ is comprised of Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW) and 9-Hole Peg Tests (9HPT).
Group
Value
95% CI
Placebo
3
Elezanumab 400mg Dose
7
Elezanumab 1800 mg Dose
9
Overall Response Score (ORS)Secondary· Week 12
The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).
Group
Value
95% CI
Placebo
-0.47
± 0.134
Elezanumab 400mg Dose
0.00
± 0.136
Elezanumab 1800 mg Dose
-0.21
± 0.139
Overall Response Score (ORS)Secondary· Week 24
The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).
Clinically significant worsening = -1, no change = 0, clinically significant improvement = +1.
The ORS is the sum of these scores for the EDSS, Timed 25-Foot Walk, 9-Hole Peg Test-dominant and 9-Hole Peg Test-non-dominant and ranges from -4 to + 4.
Group
Value
95% CI
Placebo
-0.28
± 0.176
Elezanumab 400mg Dose
-0.27
± 0.194
Elezanumab 1800 mg Dose
-0.53
± 0.188
Overall Response Score (ORS)Secondary· Week 36
The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).
Clinically significant worsening = -1, no change = 0, clinically significant improvement = +1.
The ORS is the sum of these scores for the EDSS, Timed 25-Foot Walk, 9-Hole Peg Test-dominant and 9-Hole Peg Test-non-dominant and ranges from -4 to + 4.
Group
Value
95% CI
Placebo
-0.45
± 0.159
Elezanumab 400mg Dose
-0.48
± 0.178
Elezanumab 1800 mg Dose
-0.52
± 0.169
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 76 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT03737851 — A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sc
· Phase 2
· completed
Other recruiting trials for Multiple Sclerosis (MS)
Currently open trials in the same condition.
NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
· Phase 1
· recruiting
NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
· Phase 1
· recruiting
NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest
· active not recruiting
NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS)
· NA
· recruiting
NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
· active not recruiting
Other AbbVie trials
Trials by the same sponsor.
NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants
· Phase 1
· completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W
· Phase 3
· withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult
· Phase 1
· completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China
· completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 21 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737812.